Last reviewed · How we verify
Combination Drug Therapy
Combination Drug Therapy is a Small molecule drug developed by Swedish Medical Center. It is currently in Phase 3 development. Also known as: Drug Therapy, Combination, Aspirin, Clopidogrel, Statin.
A combination drug therapy uses multiple active pharmaceutical agents with complementary mechanisms to enhance therapeutic efficacy.
Combination drug therapy is being studied in various clinical trials for conditions such as COVID-19, Head and Neck Cancer, Myelodysplastic Syndromes, Postoperative Cystoid Macular Edema, and Irvine-Gass Syndrome. Examples of interventions used in combination drug therapy include Paxlovid, a mutant p53 peptide pulsed dendritic cell vaccine, and tetanus toxoid helper peptide.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Combination Drug Therapy |
|---|---|
| Also known as | Drug Therapy, Combination, Aspirin, Clopidogrel, Statin, fluoxetine |
| Sponsor | Swedish Medical Center |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Combination therapies work by targeting multiple pathways or mechanisms simultaneously, which can improve treatment outcomes, reduce resistance development, and potentially lower required doses of individual agents. The specific mechanism depends on which drugs are combined and their individual targets.
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination Drug Therapy CI brief — competitive landscape report
- Combination Drug Therapy updates RSS · CI watch RSS
- Swedish Medical Center portfolio CI
Frequently asked questions about Combination Drug Therapy
What is Combination Drug Therapy?
How does Combination Drug Therapy work?
Who makes Combination Drug Therapy?
Is Combination Drug Therapy also known as anything else?
What development phase is Combination Drug Therapy in?
Related
- Manufacturer: Swedish Medical Center — full pipeline
- Also known as: Drug Therapy, Combination, Aspirin, Clopidogrel, Statin, fluoxetine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing